Cyr61 is involved in neutrophil infiltration in joints by inducing IL-8 production by fibroblast-like synoviocytes in rheumatoid arthritis
- Xianjin Zhu†1, 3,
- Lianbo Xiao†2,
- Rongfen Huo1,
- Jie Zhang1,
- Jinpiao Lin1,
- Jun Xie2,
- Songtao Sun2,
- Yong He2,
- Yue Sun1,
- Zhou Zhou1,
- Baihua Shen1 and
- Ningli Li1Email author
© Zhu et al.; licensee BioMed Central Ltd. 2013
Received: 20 June 2013
Accepted: 28 October 2013
Published: 13 November 2013
It is well known that neutrophils play very important roles in the development of rheumatoid arthritis (RA) and interleukin (IL)-8 is a critical chemokine in promoting neutrophil migration. We previously showed that increased production of Cyr61 by fibroblast-like synoviocytes (FLS) in RA promotes FLS proliferation and Th17 cell differentiation, thus Cyr61 is a pro-inflammatory factor in RA pathogenesis. In this study, we explored the role of Cyr61 in neutrophil migration to the joints of RA patients.
RA FLS were treated with Cyr61 and IL-8 expression was analyzed by real-time PCR and ELISA. The migration of neutrophils recruited by the culture supernatants was determined by the use of a chemotaxis assay. Mice with collagen-induced arthritis (CIA) were treated with anti-Cyr61 monoclonal antibodies (mAb), or IgG1 as a control. Arthritis severity was determined by visual examination of the paws and joint destruction was determined by hematoxylin-eosin (H&E) staining. Signal transduction pathways in Cyr61-induced IL-8 production were investigated by real-time PCR, western blotting, confocal microscopy, luciferase reporter assay or chromatin immunoprecipitation (ChIP) assay.
We found that Cyr61 induced IL-8 production by RA FLS in an IL-1β and TNF-α independent pathway. Moreover, we identified that Cyr61-induced IL-8-mediated neutrophil migration in vitro. Using a CIA animal model, we found that treatment with anti-Cyr61 mAb led to a reduction in MIP-2 (a counterpart of human IL-8) expression and decrease in neutrophil infiltration, which is consistent with an attenuation of inflammation in vivo. Mechanistically, we showed that Cyr61 induced IL-8 production in FLS via AKT, JNK and ERK1/2-dependent AP-1, C/EBPβ and NF-κB signaling pathways.
Our results here reveal a novel role of Cyr61 in the pathogenesis of RA. It promotes neutrophil infiltration via up-regulation of IL-8 production in FLS. Taken together with our previous work, this study provides further evidence that Cyr61 plays a key role in the vicious cycle formed by the interaction between infiltrating neutrophils, proliferated FLS and activated Th17 cells in the development of RA.
Human rheumatoid arthritis (RA) is a systemic inflammatory disease that involves hyperplasia of synovial tissues (ST) and structural damage to cartilage, bone and ligaments . Although the etiology and pathogenesis of RA are still unclear, there are many inflammatory cells accumulated in the synovial fluid (SF) and involved in the pathogenesis of RA . It is known that neutrophils are the most abundant cells present either in the SF of the affected joints or at the pannus/cartilage interface [3, 4]. Studies have shown that infiltrating neutrophils contribute to autoimmune arthritis development and severity . In animal models, neutrophil depletion by anti-Gr1 antibodies, an antibody for mouse neutrophils, can protect mice from arthritis; furthermore, injection of anti-Gr1 antibodies into mice after disease onset can impair the progression of arthritis [3, 6]. Moreover, blocking neutrophil development, for example, genetic deficiency of G-CSF or the G-CSF receptor, which are both critical for neutrophil development, can protect mice from collagen-induced arthritis (CIA) [7, 8]. Treatment with anti-leukoproteinase (a physiologic inhibitor of neutrophil serine proteases) not only reduces arthritis incidence and inflammation but also has a protective effect against cartilage and bone erosion [9, 10]. In RA, neutrophils are commonly recruited into diseased joints by chemoattractants and enhance tissue damage [2, 4, 5]. Notably, recent studies have shown that neutrophils can release IL-17 in inflamed ST [11, 12]. Together, these results suggest that neutrophils play important roles in the pathogenesis of RA and that affecting neutrophil migration to the diseased joints can decrease severity of RA.
IL-8/CXCL8, a potent 8.5-kDa chemoattractant for neutrophils, plays a pivotal role in the recruitment and activation of neutrophils and is considered to be the most important inflammatory chemokine associated with arthritis [13, 14]. There is a positive correlation between IL-8 and the number of neutrophils in the SF of RA patients [15, 16]. Consistently, it is found that IL-8 or its counterparts in animals is essential for inflammation mediated by neutrophils [17, 18]. For example, MIP-2 (a counterpart of human IL-8) is increased in the hind paws of CIA mice and correlates with the number of accumulated neutrophils, and administration of MIP-2 antibody (Ab) weakens inflammation of hind paws . These results indicate that IL-8 and its relative chemokines are directly involved in the pathogenesis of RA. IL-8 production is induced by many inflammatory cytokines in RA fibroblast-like synoviocytes (FLS), such as IL-1β , TNF-α [20, 21] and IL-17 , but whether there are other IL-8 expression inducers remains unknown.
Cyr61/CCN1 is a product of an immediate early gene and functions in mediating cell adhesion and inducing cell migration [22–24]. As a secreted extracellular matrix (ECM) protein, Cyr61 has much potential for activation via interacting with distinct integrins in different cells [25–27]. We reported previously that the expression of Cyr61 is greatly enhanced in FLS from RA patients, and this increased expression of Cyr61 in turn acts to further stimulate FLS proliferation and induces Th17 differentiation by promoting IL-6 production in RA [28, 29]. However, whether Cyr61 has any effect on IL-8 production and plays any roles in inflammation mediated by infiltrating neutrophils in RA has not yet been explored.
In this study, we found that Cyr61 stimulated IL-8 production by FLS in an IL-1β and TNF-α independent pathway. Cyr61 has the ability to enhance the binding of AP-1, C/EBPβ and NF-κB to the IL-8 promoter via an AKT, JNK and ERK1/2 dependent signaling pathway. Moreover, we determined that Cyr61-induced IL-8 mediated neutrophil migration in vitro. Using a CIA animal model, we found that blocking Cyr61 action with a monoclonal antibody (mAb, 093G9) reduced MIP-2 production, decreased neutrophil migration, and remarkably ameliorated disease progression in CIA mice. In conclusion, Cyr61 plays a critical role in stimulating IL-8 production by FLS in RA and contributes to recruitment of neutrophils. As IL-8 is commonly induced by IL-1β and TNF-α in the development of RA, our results indicate that Cyr61 is a novel IL-8 production inducer. Taken together with our previous work, this report provides new evidence that Cyr61 participates in RA pathogenesis as a pro-inflammatory factor and plays a key role in the vicious cycle formed by cross-talk among activated Th17, proliferated FLS and infiltrating neutrophils in the development of RA.
Male, DBA/1 J mice, six- to eight-weeks old, were purchased from the Shanghai Laboratory Animal Center, Chinese Academy of Science. Mice were maintained under pathogen-free conditions. All experiments were performed in accordance with guidelines and approved by the Animal Care and Use Committee of Shanghai Jiaotong University School of Medicine (2013028).
Patients and specimens
A total of 46 RA patients (6 men and 40 women, 30- to 84-years old, mean and SD 57 ± 12 years) were included in the study. The disease duration of the RA patients was 16 ± 9 years. The diagnosis of RA was based on the revised criteria of the American College of Rheumatology . The control subjects were 27 osteoarthritis (OA) patients fulfilling the diagnostic criteria of OA proposed by Altman . Clinical characteristics of RA and OA patients are given in Additional file 1: Table S1. ST were obtained from patients and FLS were cultured and identified as reported previously . SF and cell culture supernatants were collected as reported previously . The study was approved by the Institutional Medical Ethics Review Board of the Shanghai Jiaotong University School of Medicine and informed consent was obtained from each of the individuals.
Synovial fluid and synovial tissue cell preparation and flow cytometric analysis
To prepare single-cell suspensions from SF and ST, SF specimens were centrifuged at 500 g for 10 minutes, and cells were collected, counted and resuspended in phosphate-buffered saline (PBS) for flow cytometric analysis; ST specimens were minced into small pieces and incubated for two hours with 1 mg/ml type I collagenase (Sigma-Aldrich, Bornem, Belgium) in (D)MEM at 37°C, then cells were collected by filtering the suspension through nylon mesh and immediately used for flow cytometric analysis. For surface markers staining, fluorescence conjugated CD3, CD11b, CD14, CD15, CD16 and CD19 (eBiosciences, San Diego, CA, USA) antibodies were used. Flow cytometry was performed using a FACS Calibur cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using Cellquest software (BD Biosciences).
Real-time PCR analysis
Total RNA was extracted from cells and real-time PCR was performed as previously reported . Briefly, total RNA was extracted from specimens using a Tripure isolation reagent (Roche Diagnostics, Indianapolis, IN, USA), according to the manufacturer’s instructions. The RNA quality and quantity were evaluated by a NanoDrop ND-1000 Spectrophotometer (NanoDrop, Wilmington, DE, USA). The integrity of RNA was appraised with gel analysis for the intact 28S and 18S ribosomal RNA. Messenger RNA (mRNA) was converted to cDNA using a RevertAidTM First Strand cDNA Synthesis Kit (Thermo Scientific, Glen Burnie, MD, USA) according to the manufacturer’s instructions. Real-time PCR was performed using SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. The primers used in this study are shown in Additional file 1: Table S2.
RNAi knockdown of gene expression
Cyr61, IL-1β and TNF-α small interfering RNA (siRNA, Additional file 1: Table S3) were designed and synthesized at Shanghai GenePharma (Shanghai, China) and gene knockdowns were performed as previously reported [28, 29]. In brief, FLS were cultured in 24-well plates. A transfection mixture of siRNA oligonucleotides and Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) in serum-free medium was added to medium-aspirated cells for four hours. Then, the medium was replaced with complete (D)MEM containing 10% fetal bovine serum for an additional 24 hour incubation.
Probing of signaling pathways involved in Cyr61 induced IL-8 production
Special inhibitors of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways were purchased from Sigma-Aldrich and used to analyze Cyr6-induced IL-8 production. Briefly, 4 μM pyrrolidine dithiocarbamate (PDTC; an inhibitor of NF-κB activation), 10 μM SB203580 (an inhibitor of p38 MAPK), 1 μM PD98059 (an inhibitor of ERK1/2), or 20 μM SP600125 (an inhibitor of JNK) was added to the cell culture together with 5 μg/ml Cyr61 at the same time; then expression of IL-8 was determined using real-time PCR and the concentration of IL-8 in the supernatant was evaluated by ELISA. The activations of AKT, JNK, ERK1/2 and NF-κB were analyzed using western blotting with specific antibodies.
The concentration of IL-8 in the cell culture supernatant and SF was determined by a sandwich ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. The level of Cyr61 was measured by ELISA as described previously .
Western blot analysis
Protein immune blotting was performed as described previously . In brief, tissue or cell lysates were separated by SDS–PAGE electrophoresis and then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore Corporation, Bedford, MA, USA) at 100 v for 90 minutes. The phosphorylation of AKT, JNK, ERK1/2 and NF-κB and the expression of MIP-2 were analyzed using specific antibodies (Cell Signaling Technology Inc, Beverly, MA, USA). After washing with PBS, the membranes were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) at room temperature for one hour followed by washing with PBS. The target proteins were examined with an ECL system (Millipore Corporation, Bedford, MA, USA) and visualized with autoradiography film.
Confocal laser scanning fluorescence microscopy assay
NF-κB nuclear translocation in FLS was studied with a confocal laser scanning fluorescence microscopy (LSM510; Zeiss, Jena, Germany) technique as described before . In brief, FLS grown on glass coverslips were stimulated with 5 ug/ml Cyr61 for 30 minutes and fixed with acetone. The fixed cells were stained overnight with anti-NF-κB p65 antibody (Cell Signaling Technology Inc) and incubated for one additional hour with a PE-labeled secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing, cells were incubated for three minutes with 0.25 mg/ml of 4,6-diamidino-2-phenylindole and examined using an LSM 510 confocal fluorescence microscope.
Neutrophils were isolated from peripheral blood of healthy donors according to the manufacturer’s instructions. In brief, venous blood was drawn and neutrophils were isolated immediately by Polymorphprep (Axis-Shield PoC AS, Oslo, Norway). After lysis of the erythrocytes, the neutrophils were harvested, washed twice with physiological saline and resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum at a cell concentration of 106/ml. The purified cells consisted of a more than 95% pure population of viable neutrophils, as assessed by morphology and the trypan blue exclusion test.
Chemotaxis was assessed using 24-transwell Boyden chambers of 3 μm pore size (Corning Costar, Cambridge, MA, USA) for neutrophils. FLS were plated in 24-well plates and stimulated with 5 μg/ml Cyr61 (PeproTech, Rocky Hill, NJ, USA) for 48 hours. Then, the culture supernatant was harvested and pre-incubated with anti-IL-8 mAb, (5 μg/mL, PeproTech) or control mAb (5 μg/ml, PeproTech) for one hour. Then, the treated supernatant was added to the lower chambers, while neutrophils were added to the top chambers for incubation for another 90 minutes at 37°C in a humidified atmosphere with 5% carbon dioxide. The filters were fixed with ethanol and stained with crystal violet. The chemotactic response was then determined by evaluating the number of cells that had migrated through the entire thickness of the filter. Triplicate chambers were used in each experiment and five fields were examined in each filter. The results were expressed as the chemotactic index, being the number of cells that migrated towards the sample divided by the number of cells that migrated towards the control medium.
Construction of luciferase reporter plasmids
The 181 bp IL-8 promoter sequences (-135 to +46) were PCR amplified from human genomic DNA using the following primers, IL-8 (WT)-Forward: 5′-GTGAGATCTG AAGTGTGATGACTCAGG-3′, which contains an artificial BglII site, and IL-8 (WT)-Reverse: 5′-GTGAAGCTTGAAGCTTGTGTGCTCTGC-3′, which contains an artificial HindIII site . The PCR product was then digested with BglII/HindIII and inserted into the corresponding restriction sites of the luciferase reporter plasmid pGL3-Basic (Promega, Fitchburg, WI, USA) to generate IL-8 (WT) Luc. To generate the IL-8 (mAP-1) Luc, IL-8 (mNF-κB) Luc and IL-8 (mC/EBP) Luc vector that contains the same IL-8 promoter sequences but with mutation that distorts the AP-1, NF-κB and C/EBP consensus, the forward primers (Additional file 1: Table S4) were used together with IL-8 (WT)-Reverse . The PCR products were again digested with BglII/HindIII and ligated into pGL3-Basic.
Cell culture, transfection and reporter assay
Human skin fibroblasts (HSFs) were cultured in (D)MEM supplemented with 10% fetal bovine serum. For transient transfections, cells were grown to 70% to 80% confluence in 24-well dishes and maintained serum-free prior to transfection; then, cells were transfected with IL-8WT, IL-8mAP-1, IL-8mC/EBP or IL-8mNF-κB along with pRL-TK using the liposome–mediated method with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. After a 24-hour incubation period, cells were treated with Cyr61 (5 μg/mL) for an additional two hours, at which time luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer’s instructions.
Chromatin immunoprecipitation assay
For chromatin immunoprecipitation (ChIP) assay, FLS cells, either with or without Cyr61 protein (5 μg/mL) stimulation, were cross-linked by formaldehyde fixation. Following cellular and nuclear lysis, isolated chromatin was sheared by sonication and subsequently incubated overnight at 4°C with antibodies against c-Jun, NF-κB p65 (Cell Signaling Technology Inc, Danvers, MA, USA), C/EBPβ (Santa Cruz Biotechnology), or control rabbit IgG (PeproTech). Immunocomplexes were subjected to cross-link reversal, extracted and precipitated as described in the protocol according to the manufacturer’s instructions. The eluted DNA and the aliquots of chromatin prior to immunoprecipitation (input) were subjected to semiquantitative PCR. The PCR primers were used for amplifying IL-8 promoters (-125 to +11) with the following sequences: -125 forward, 5′-ACTCAGGTTTGCCC TGAGGGGA-3′ and +11 reverse, 5′-TGCCTTATGGAGTGCTCCGGTG -3′. The PCR conditions were as follows: one cycle at 95°C for five minutes; 34 cycles at 95°C for 30 seconds, 65°C for 30 seconds, and 72°C for one minute; one cycle at 72°C for five minutes. PCR products were separated by 2% agarose gel containing ethidium bromide. Densitometry was used to quantify the PCR results, and all results were normalized by respective input values.
Establishment and treatment of collagen-induced arthritis
CIA was induced as described previously . Briefly, male DBA/1 J mice were injected intradermally with 150 μg of chicken type II collagen (Chondrex, Redmond, WA, USA) in 0.05 M acetic acid emulsified in Freund’s complete adjuvant. Booster injections were administered on day 21 with a total of 75 μg collagen II in Freund’s incomplete adjuvant. Joint inflammation was evaluated on a scale of 1 to 4 , with a maximum clinical score of 16 per mouse. Mice were treated with control IgG1 or anti-Cyr61 mAb 093G9 generated in our laboratory (200 μg/mouse) twice a week when the score reached 2.
The joints were removed from sacrificed CIA mice and fixed in 10% phosphate-buffered formalin, decalcified in 10% ethylenediaminetetraacetic acid (EDTA), embedded in paraffin, stained with H & E and examined by light microscopy according to standard protocols.
Slides were deparaffinized through a series of xylene baths and rehydrated through graded alcohols. The sections were then immersed in methanol containing 0.3% hydrogen peroxide for 20 minutes to block endogenous peroxidase activity and incubated in 2.5% blocking serum to reduce nonspecific binding. Sections were incubated overnight at 4°C with anti-human CD15 mAb or anti-mouse Gr-1 mAb (eBiosciences); mouse IgM or rat IgG was used as negative control in the study. Slides were then incubated in anti-mouse IgM HRP or anti-rat IgG HRP. Vector NovaRED substrate (Vector Labs, Burlinghame, CA, USA) was used as the peroxidase substrate and slides were counter-stained with a hematoxylin solution. Stained sections were dehydrated and then mounted by light microscopy.
All experiments were performed in triplicate. The difference among groups was determined by analysis of variance (ANOVA) and comparison between two groups was analyzed by the t-test using the GraphPad Prism 4.0 (GraphPad Software, In c., San Diego, CA, USA). A value of P <0.05 was considered statistically significant.
Neutrophils were abundant in inflamed joints of patients with RA
Cyr61 induced IL-8 production by FLS of RA patients
IL-1β and TNF-α were not involved in Cyr61-induced IL-8 production by FLS
Cyr61-induced IL-8 secretion by FLS stimulated the migration of neutrophils
Blocking Cyr61 ameliorated inflammation and down-regulated the expression of MIP-2 in vivo
Cyr61-induced IL-8 production in FLS depends on AKT, JNK and ERK1/2 activation
Cyr61 increased c-Jun, C/EBPβ and p65 binding to the response element in the IL-8 promoter
Although Th17 cells are newly identified inflammation cells in the pathogenesis of RA [43–45], a number of studies have revealed that neutrophils also play a pivotal role in the initiation and progression of RA [2–5]. As the most abundant cells infiltrating either in the SF of the affected joints or at the pannus/cartilage interface in RA, neutrophils are able to release cytotoxic mediators, cytokines and chemokines into the site of inflammation, leading to tissue damage and cartilage destruction [2–5, 36]. Moreover, recently, some studies showed that neutrophils have an interaction with Th17 cells  and can release IL-17 in inflamed ST [11, 12], adding a novel role for neutrophils in the initiation of RA. Considering that promoting neutrophil migration into the site of inflammation is critical for strengthening the cross-talk between neutrophils and Th17 cells, finding new inducers for increasing production of IL-8, a strong chemoattractant for neutrophil recruitment, is critical for developing a new strategy for RA treatment.
CCN1/Cyr61, as a member of the growth factor-inducible immediate-early genes, belongs to the CCN family [22, 27] and is known as a novel pro-inflammatory factor [47–50]. Our studies have established that over-expressed Cyr61 not only stimulates FLS proliferation in an autocrine manner , but also initiates Th17 cell differentiation by promoting IL-6 production in FLS . Considering that FLS are a source of Cyr61 and other inflammatory proteins , we asked whether Cyr61 is involved in IL-8 production by FLS in RA.
In this study, we first examined the amount of neutrophils infiltrated in SF and ST derived from RA patients. The results suggested that neutrophils were abundant in both SF and ST, which is consistent with previous reports . Further, we found that Cyr61 was able to induce IL-8 mRNA expression and increase protein synthesis in FLS from RA patients. Given that studies have shown that IL-1β or/and TNF-α induce IL-8 production in RA FLS [19–21], we evaluated whether IL-1β and TNF-α were involved in the Cyr61-induced IL-8 production in FLS. By RNAi technology, we demonstrated that Cyr61-promoted IL-8 production was not dependent on an IL-1β and TNF-α pathway. As IL-8 is a critical chemokine that functions in promoting neutrophil migration, we tested whether Cyr61-induced IL-8 in RA FLS could stimulate neutrophil migration and found that it was indeed the case. Taken together, these results strongly indicate that Cyr61 induces IL-8 production by an IL-1β and TNF-α independent pathway, promotes the migration of neutrophils into joints and enhances the initiation and progression of RA inflammation. Indeed, in our study, we found that administration of a specific anti-Cyr61 antibody in CIA mice not only ameliorated inflammation, but also down-regulated the expression of MIP-2 (a counterpart of human IL-8) and impaired the infiltration of neutrophils in ST in vivo.
It is known that IL-1β and TNF-α are very important cytokines in inflammation and tissue damage that promote the synthesis of inflammatory proteins, including IL-8 for recruiting neutrophils [20, 52]. Anti-IL-1β and TNF-α treatments in RA show efficacy in inhibiting inflammation and tissue erosion [53, 54]. Nevertheless, some side-effects of cytokine-based therapy have been reported, including susceptibility to serious infection and malignancies [53, 54]. Thus, it is very essential to find new therapeutic options for the treatment of RA. Our current study revealed that Cyr61, as extracellular matrix produced by FLS, promotes IL-8 in an IL-1β and TNF-α independent manner; blocking Cyr61 action might be of benefit by avoiding the side-effects of anti-IL-1/TNFα-based therapy. Together with our previous findings that Cyr61 promotes FLS proliferation and IL-6 production, Cyr61 plays a critical role in the inflammation and tissue damage caused by RA, suggesting that targeting Cyr61 may be an effective means for the treatment of RA.
How does Cyr61 induce IL-8 production in FLS?
Activation of MAPK and NF-κB pathways have been shown to contribute to IL-8 expression [37, 42, 55, 56], but the role of MAPK and the NF-κB pathway for the Cyr61-induced IL-8 production in FLS remains to be determined. To address the signaling pathway of Cyr61 promoting IL-8 production in FLS, we evaluated the profile of AKT/NF-κB, a well-known Cyr61/integrins pathway , and three well-defined MAPK pathways (JNK, ERK and p38). As expected, AKT/NF-κB pathways contributed to Cyr61-induced IL-8 production in FLS. However, the analysis of MAPK pathways indicated that JNK and ERK pathways were involved in the Cyr61-induced IL-8 production in FLS. Interestingly, the p38 pathway was not found to contribute to the Cyr61-induced IL-8 production in FLS. Previous observations suggested that, in the IL-1β or TNF-α induced IL-8 production, the p38 MAPK pathway contributes to IL-8 gene expression by stabilizing mRNAs in RA FLS [42, 58]. Our study first shows that the p38 MAPK pathway was not involved in the Cyr61-induced IL-8 production in FLS; in other words, signaling cascades of Cyr61-induced IL-8 production are different from signaling pathways of IL-1β or TNF-α-induced IL-8 production. Considering the role of the p38 MAPK pathway in post transcriptional regulation of IL-8 production, how to stabilize the mRNAs of IL-8 in Cyr61-stimulated FLS is under investigation.
Based on the results of Cyr61-induced IL-8 production in FLS via JNK, ERK and NF-κB activation, we examined the transcriptional mechanisms regulated by Cyr61. Although it is well known that the core IL-8 promoter contains binding sites for AP-1, C/EBP and NF-κB, the different binding activity of AP-1, C/EBP and NF-κB on the IL-8 promoter has been attributed to different IL-8 production in the cells [37, 42]. We performed promoter-reporters and ChIP analysis for testing regulatory elements of the IL-8 promoter in Cyr61-treated FLS. The results showed that AP-1/c-Jun, C/EBPβ and NF-κB binding to the IL-8 promoter were all necessary for Cyr61-induced IL-8 expression in RA FLS. Earlier studies have documented that transcription factors involved in IL-8 gene transcription interact to facilitate the formation of an enhanceosome-like structure that favors the induction of the IL-8 promoter . In our studies, we found that Cyr61 enhanced AP-1, C/EBPβ and NF-κB binding to the IL-8 promoter simultaneously, suggesting that signaling pathways mediated by Cyr61 provoke an interaction among these transcription factors and may contribute to the formation of an enhanceosome-like structure for IL-8 production in RA FLS, even though the p38 MAPK pathway was not active in Cyr61-induced IL-8 production in RA FLS. Based on these results, we propose that Cyr61 is able to induce IL-8 production similar to pro-inflammatory cytokines, by which Cyr61 enhances neutrophil infiltration in joints with RA.
Although a recent study showed that hypoxia might induce Cyr61 and IL-8 secretion in nasal polyp fibroblasts, no direct evidence demonstrated that Cyr61 induces IL-8 production under an inflammatory environment via an IL-1β/TNF-α independent pathway . Considering that Cyr61 expression may be up-regulated as a protective response to hypoxia in vivo, it would be interesting to investigate whether hypoxia can enhance Cyr61-induced IL-8 production by RA FLS.
Our study indicated for the first time, that Cyr61 is a novel IL-8 production inducer and initiates the pathogenesis mediated by neutrophils. Combining the observation that infiltrating neutrophils and Th17 form an inflammatory cross-talk with our previous findings that Cyr61 promotes Th17 development and FLS proliferation [28, 29, 46], we suggest that Cyr61 plays a key role in the vicious cycle formed by interaction among activated Th17, proliferated FLS and infiltrating neutrophils in the development of RA. Thus, targeting Cyr61 might be an effective strategy in RA treatment.
(Dulbecco’s) modified Eagle’s medium
Enzyme-linked immunosorbent assay
- H & E:
Hematoxylin and eosin
Human skin fibroblasts
Mitogen-activated protein kinase
Real-time polymerase chain reaction
Small interfering RNA
Tumor necrosis factor-α.
This work was supported by the National Basic Research Program of China (2010CB529103), Jiangsu Province-BL2013034, National Natural Science Foundation of China (81072468, 81172856), Science and Technology Commission of Shanghai Municipality (12JC1407700, 12DZ1941802, 12401903700/2,134119b1500, ZYSNXD-CC-ZDYJ054), Shanghai Municipal Education (J50207).
- Firestein: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.View ArticlePubMedGoogle Scholar
- Cascao R, Rosario HS, Souto-Carneiro MM, Fonseca JE: Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev. 2010, 9: 531-535. 10.1016/j.autrev.2009.12.013.View ArticlePubMedGoogle Scholar
- Wipke BT, Allen PM: Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol. 2001, 167: 1601-1608.View ArticlePubMedGoogle Scholar
- Kitsis E, Weissmann G: The role of the neutrophil in rheumatoid arthritis. Clin Orthop Relat Res. 1991, 265: 63-72.PubMedGoogle Scholar
- Nemeth T, Mocsai A: The role of neutrophils in autoimmune diseases. Immunol Lett. 2012, 143: 9-19. 10.1016/j.imlet.2012.01.013.View ArticlePubMedGoogle Scholar
- Tanaka D, Kagari T, Doi H, Shimozato T: Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology. 2006, 119: 195-202. 10.1111/j.1365-2567.2006.02424.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Lawlor KE, Campbell IK, Metcalf D, O’Donnell K, van Nieuwenhuijze A, Roberts AW, Wicks IP: Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci USA. 2004, 101: 11398-11403. 10.1073/pnas.0404328101.PubMed CentralView ArticlePubMedGoogle Scholar
- Eyles JL, Hickey MJ, Norman MU, Croker BA, Roberts AW, Drake SF, James WG, Metcalf D, Campbell IK, Wicks IP: A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood. 2008, 112: 5193-5201. 10.1182/blood-2008-02-139535.View ArticlePubMedGoogle Scholar
- Sehnert B, Cavcic A, Bohm B, Kalden JR, Nandakumar KS, Holmdahl R, Burkhardt H: Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis. Arthritis Rheum. 2004, 50: 2347-2359. 10.1002/art.20339.View ArticlePubMedGoogle Scholar
- Sehnert B, Gierer P, Ibrahim S, Kuhl A, Voll R, Nandakumar KS, Holmdahl R, Hallmann R, Vollmar B, Burkhardt H: Modulation of granulocyte-endothelium interactions by antileukoproteinase: inhibition of anti-type II collagen antibody-induced leukocyte attachment to the synovial endothelium. Arthritis Res Ther. 2006, 8: R95-10.1186/ar1973.PubMed CentralView ArticlePubMedGoogle Scholar
- Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strieter RM, Rosin DL, Okusa MD: IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010, 120: 331-342. 10.1172/JCI38702.PubMed CentralView ArticlePubMedGoogle Scholar
- Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ: IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One. 2011, 6: e24048-10.1371/journal.pone.0024048.PubMed CentralView ArticlePubMedGoogle Scholar
- Kobayashi Y: The role of chemokines in neutrophil biology. Front Biosci. 2008, 13: 2400-2407. 10.2741/2853.View ArticlePubMedGoogle Scholar
- Szekanecz Z, Vegvari A, Szabo Z, Koch AE: Chemokines and chemokine receptors in arthritis. Front Biosci (School Ed). 2010, 2: 153-167.View ArticleGoogle Scholar
- Peichl P, Ceska M, Effenberger F, Haberhauer G, Broell H, Lindley IJ: Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol. 1991, 34: 333-339. 10.1111/j.1365-3083.1991.tb01554.x.View ArticlePubMedGoogle Scholar
- Rampart M, Herman AG, Grillet B, Opdenakker G, Van Damme J: Development and application of a radioimmunoassay for interleukin-8: detection of interleukin-8 in synovial fluids from patients with inflammatory joint disease. Lab Invest. 1992, 66: 512-518.PubMedGoogle Scholar
- Akahoshi T, Endo H, Kondo H, Kashiwazaki S, Kasahara T, Mukaida N, Harada A, Matsushima K: Essential involvement of interleukin-8 in neutrophil recruitment in rabbits with acute experimental arthritis induced by lipopolysaccharide and interleukin-1. Lymphokine Cytokine Res. 1994, 13: 113-116.PubMedGoogle Scholar
- Kagari T, Doi H, Shimozato T: The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol. 2002, 169: 1459-1466.View ArticlePubMedGoogle Scholar
- Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM: Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol. 2000, 165: 7199-7206.View ArticlePubMedGoogle Scholar
- Choi HM, Oh da H, Bang JS, Yang HI, Yoo MC, Kim KS: Differential effect of IL-1beta and TNFalpha on the production of IL-6, IL-8 and PGE2 in fibroblast-like synoviocytes and THP-1 macrophages. Rheumatol Int. 2010, 30: 1025-1033. 10.1007/s00296-009-1089-y.View ArticlePubMedGoogle Scholar
- Katz Y, Nadiv O, Beer Y: Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a “fine-tuning cytokine” in inflammation processes. Arthritis Rheum. 2001, 44: 2176-2184. 10.1002/1529-0131(200109)44:9<2176::AID-ART371>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Kireeva ML, Mo FE, Yang GP, Lau LF: Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol. 1996, 16: 1326-1334.PubMed CentralPubMedGoogle Scholar
- Menendez JA, Mehmi I, Griggs DW, Lupu R: The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 2003, 10: 141-152. 10.1677/erc.0.0100141.View ArticlePubMedGoogle Scholar
- Chen CC, Lau LF: Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 2009, 41: 771-783. 10.1016/j.biocel.2008.07.025.PubMed CentralView ArticlePubMedGoogle Scholar
- Leu SJ, Lam SC, Lau LF: Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem. 2002, 277: 46248-46255. 10.1074/jbc.M209288200.View ArticlePubMedGoogle Scholar
- Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP, Ye RD, Lau LF, Lam SC: Identification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood. 2002, 99: 4457-4465. 10.1182/blood.V99.12.4457.View ArticlePubMedGoogle Scholar
- Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R: A novel CYR61-triggered ‘CYR61-alphavbeta3 integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene. 2005, 24: 761-779. 10.1038/sj.onc.1208238.View ArticlePubMedGoogle Scholar
- Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He D, Ouyang G, Lin J, Shen B, Shi Y, Zhang Y, Li D, Li N: A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2009, 60: 3602-3612. 10.1002/art.24999.View ArticlePubMedGoogle Scholar
- Lin J, Zhou Z, Huo R, Xiao L, Ouyang G, Wang L, Sun Y, Shen B, Li D, Li N: Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rheumatoid arthritis. J Immunol. 2012, 188: 5776-5784. 10.4049/jimmunol.1103201.View ArticlePubMedGoogle Scholar
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62: 2569-2581. 10.1002/art.27584.View ArticlePubMedGoogle Scholar
- Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986, 29 (8): 1039-1049. 10.1002/art.1780290816.View ArticlePubMedGoogle Scholar
- Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS: Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem. 1999, 274: 16085-16096. 10.1074/jbc.274.23.16085.View ArticlePubMedGoogle Scholar
- Wu GD, Lai EJ, Huang N, Wen X: Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. The role of Oct-1 as a transcriptional repressor. J Biol Chem. 1997, 272: 2396-2403. 10.1074/jbc.272.4.2396.View ArticlePubMedGoogle Scholar
- Kim JM, Ho SH, Park EJ, Hahn W, Cho H, Jeong JG, Lee YW, Kim S: Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum. 2002, 46: 793-801. 10.1002/art.10113.View ArticlePubMedGoogle Scholar
- Mauri C, Mars LT, Londei M: Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med. 2000, 6: 673-679. 10.1038/76251.View ArticlePubMedGoogle Scholar
- Mohr W, Westerhellweg H, Wessinghage D: Polymorphonuclear granulocytes in rheumatic tissue destruction. III. An electron microscopic study of PMNs at the pannus-cartilage junction in rheumatoid arthritis. Ann Rheum Dis. 1981, 40: 396-399. 10.1136/ard.40.4.396.PubMed CentralView ArticlePubMedGoogle Scholar
- Roebuck KA: Regulation of interleukin-8 gene expression. J Interferon Cytokine Res. 1999, 19: 429-438. 10.1089/107999099313866.View ArticlePubMedGoogle Scholar
- Du F, Wang L, Zhang Y, Jiang W, Sheng H, Cao Q, Wu J, Shen B, Shen T, Zhang JZ, Bao C, Li D, Li N: Role of GADD45 beta in the regulation of synovial fluid T cell apoptosis in rheumatoid arthritis. Clin Immunol. 2008, 128: 238-247. 10.1016/j.clim.2008.03.523.View ArticlePubMedGoogle Scholar
- Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B, Wang R, Li N: A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 2012, 61: 677-687. 10.1007/s00262-011-1135-y.View ArticlePubMedGoogle Scholar
- Hayden MS, Ghosh S: NF-kappaB in immunobiology. Cell Res. 2011, 21: 223-244. 10.1038/cr.2011.13.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002, 2: 725-734. 10.1038/nri910.View ArticlePubMedGoogle Scholar
- Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M: Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002, 72: 847-855.PubMedGoogle Scholar
- Pernis AB: Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med. 2009, 265: 644-652. 10.1111/j.1365-2796.2009.02099.x.View ArticlePubMedGoogle Scholar
- Sarkar S, Fox DA: Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am. 2010, 36: 345-366. 10.1016/j.rdc.2010.02.006.View ArticlePubMedGoogle Scholar
- Hot A, Miossec P: Effects of interleukin (IL)-17A and IL-17 F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis. 2011, 70: 727-732. 10.1136/ard.2010.143768.View ArticlePubMedGoogle Scholar
- Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, Cosmi L, Lunardi C, Annunziato F, Romagnani S, Cassatella MA: Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010, 115: 335-343. 10.1182/blood-2009-04-216085.View ArticlePubMedGoogle Scholar
- Jun JI, Lau LF: Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov. 2011, 10: 945-963. 10.1038/nrd3599.PubMed CentralView ArticlePubMedGoogle Scholar
- Kular L, Pakradouni J, Kitabgi P, Laurent M, Martinerie C: The CCN family: a new class of inflammation modulators?. Biochimie. 2011, 93: 377-388. 10.1016/j.biochi.2010.11.010.View ArticlePubMedGoogle Scholar
- Lau LF: CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci. 2011, 68: 3149-3163. 10.1007/s00018-011-0778-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Bai T, Chen CC, Lau LF: Matricellular protein CCN1 activates a proinflammatory genetic program in murine macrophages. J Immunol. 2010, 184: 3223-3232. 10.4049/jimmunol.0902792.PubMed CentralView ArticlePubMedGoogle Scholar
- Bottini N, Firestein GS: Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013, 9: 24-33.PubMed CentralView ArticlePubMedGoogle Scholar
- Dinarello CA: The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002, 20: S1-S13.PubMedGoogle Scholar
- Botsios C: Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev. 2005, 4: 162-170. 10.1016/j.autrev.2004.09.001.View ArticlePubMedGoogle Scholar
- Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295: 2275-2285. 10.1001/jama.295.19.2275.View ArticlePubMedGoogle Scholar
- Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, Malinin NL, Cooper JA, Resch K, Kracht M: Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol. 1999, 19: 6742-6753.PubMed CentralPubMedGoogle Scholar
- Harimaya A, Koizumi J, Fujii N, Himi T: Interleukin-8 induction via NF-kappaB, p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 pathways in human peripheral blood mononuclear cells by Alloiococcus otitidis. Int J Pediatr Otorhinolaryngol. 2007, 71: 1465-1470. 10.1016/j.ijporl.2007.06.003.View ArticlePubMedGoogle Scholar
- Chen Y, Du XY: Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem. 2007, 100: 1337-1345. 10.1002/jcb.21194.View ArticlePubMedGoogle Scholar
- Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N, Okamoto T: The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts. FEBS Lett. 2000, 465: 23-27. 10.1016/S0014-5793(99)01717-2.View ArticlePubMedGoogle Scholar
- Shun CT, Lin SK, Hong CY, Huang HM, Liu CM: Hypoxia induces cysteine-rich 61, vascular endothelial growth factor, and interleukin-8 expressions in human nasal polyp fibroblasts: an implication of neutrophils in the pathogenesis of nasal polyposis. Am J Rhinol Allergy. 2011, 25: 15-18. 10.2500/ajra.2011.25.3557.View ArticlePubMedGoogle Scholar
- Jin Y, Kim HP, Cao J, Zhang M, Ifedigbo E, Choi AM: Caveolin-1 regulates the secretion and cytoprotection of Cyr61 in hyperoxic cell death. FASEB J. 2009, 23: 341-350.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.